Get the Stockscreener App
25.91
1.93%
0.49
Immunovant Inc stock is traded at $25.91, with a volume of 1.73M.
It is up +1.93% in the last 24 hours and up +17.67% over the past month.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.
See More
Previous Close:
$25.42
Open:
$25.58
24h Volume:
1.73M
Relative Volume:
1.00
Market Cap:
$5.22B
Revenue:
-
Net Income/Loss:
$-382.71M
P/E Ratio:
-9.8893
EPS:
-2.62
Net Cash Flow:
$-325.64M
1W Performance:
-0.96%
1M Performance:
+17.67%
6M Performance:
+54.13%
1Y Performance:
+2.86%
1-Day Range:
$25.48
$26.62
1-Week Range:
$24.95
$26.62
52-Week Range:
$12.72
$27.69
Immunovant Inc Stock (IMVT) Company Profile
Name
Immunovant Inc
Sector
Industry
Phone
917-580-3099
Address
320 WEST 37TH STREET, NEW YORK, NY
Compare IMVT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMVT
Immunovant Inc
|
25.91 | 5.12B | 0 | -382.71M | -325.64M | -2.62 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Immunovant Inc Stock (IMVT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-14-25 | Initiated | Truist | Hold |
| Jul-10-25 | Resumed | Goldman | Neutral |
| Mar-03-25 | Initiated | Jefferies | Hold |
| Jan-03-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Oct-09-24 | Reiterated | Oppenheimer | Outperform |
| Mar-28-24 | Initiated | Oppenheimer | Outperform |
| Mar-13-24 | Initiated | Goldman | Buy |
| Feb-20-24 | Initiated | JP Morgan | Overweight |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Oct-13-23 | Upgrade | UBS | Neutral → Buy |
| Sep-26-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-01-23 | Initiated | BofA Securities | Buy |
| Apr-25-23 | Initiated | Citigroup | Buy |
| Mar-31-23 | Initiated | Piper Sandler | Overweight |
| Mar-30-23 | Initiated | Stifel | Buy |
| Feb-15-23 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-13-23 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-03-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Sep-26-22 | Downgrade | UBS | Buy → Neutral |
| Dec-08-21 | Initiated | Wells Fargo | Equal Weight |
| Aug-03-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Aug-02-21 | Downgrade | Credit Suisse | Neutral → Underperform |
| Jun-01-21 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-01-21 | Downgrade | Stifel | Buy → Hold |
| Oct-28-20 | Initiated | UBS | Buy |
| Oct-12-20 | Initiated | Guggenheim | Buy |
| Oct-08-20 | Initiated | Stifel | Buy |
| Oct-02-20 | Initiated | Credit Suisse | Outperform |
| Aug-26-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-25-20 | Initiated | Raymond James | Outperform |
| Jul-29-20 | Initiated | H.C. Wainwright | Buy |
| Feb-24-20 | Initiated | SVB Leerink | Outperform |
View All
Immunovant Inc Stock (IMVT) Latest News
Wolfe Research Downgrades Immunovant (IMVT) - MSN
(IMVT) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Immunovant (NASDAQ:IMVT) Nasdaq Today Immunology Innovation - Kalkine Media
Immunovant, Inc. (NASDAQ:IMVT) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
How Investors Are Reacting To Immunovant (IMVT) $550 Million Follow-On Equity Raise And Dilution - Sahm
Assenagon Asset Management S.A. Invests $3.31 Million in Immunovant, Inc. $IMVT - MarketBeat
Research Analysts Issue Forecasts for Immunovant Q3 Earnings - MarketBeat
Momentum Shift: How Immunovant Inc. stock responds to policy changesChart Signals & Consistent Income Trade Recommendations - Улправда
How Immunovant Inc. stock compares to growth peers2025 Top Gainers & Technical Confirmation Alerts - Улправда
Squarepoint Ops LLC Has $1.36 Million Stock Position in Immunovant, Inc. $IMVT - MarketBeat
How Immunovant Inc. stock responds to policy changesInflation Watch & Long-Term Safe Return Strategies - ulpravda.ru
Tuyl Christopher Van Sells 10,813 Shares of Immunovant (NASDAQ:IMVT) Stock - MarketBeat
Officer Van Tuyl Acquires 16,676 Of Immunovant Inc [IMVT] - TradingView — Track All Markets
Immunovant Executive Sells Shares to Cover Tax Obligations - TradingView — Track All Markets
First Week of IMVT February 2026 Options Trading - Nasdaq
Can Immunovant Inc. stock weather global recessionPortfolio Growth Summary & Low Drawdown Investment Strategies - DonanımHaber
Is Immunovant Stock a Buy After Roivant Sciences Increased Its Stake by $350 Million? - AOL.com
Is Immunovant Stock a Buy After Roivant Sciences Increased Its Stake by $350 Million? - The Motley Fool
Share Offerings Prompt Huge Insider Buying in These 3 Biotechs - AOL.com
Immunovant (IMVT) Is Up 14.0% After Roivant-Backed $550 Million Equity Raise For IMVT-1402Has The Bull Case Changed? - Yahoo Finance
The Goldman Sachs Group Forecasts Strong Price Appreciation for Immunovant (NASDAQ:IMVT) Stock - MarketBeat
Immunovant (IMVT) Is Up 14.0% After $550 Million Follow-On Backed By Roivant SciencesWhat's Changed - Sahm
Immunovant (IMVT) Stock News and Forecast for Dec. 14, 2025: $550M Financing Closes, Roivant Buys $350M, Analysts Update Targets - ts2.tech
Immunovant (IMVT) down 0.6% since last earnings report: Can it rebound? - MSN
EPS Watch: Why OrthoPediatrics Corp. stock appeals to dividend seekersWeekly Stock Report & Low Drawdown Trading Strategies - moha.gov.vn
Immunovant Raises $550 Million Through Stock Offering - The Globe and Mail
Insider Buying: Sciences Roivant Acquires 16,666,666 Shares of I - GuruFocus
Oppenheimer Maintains Outperform Rating on Immunovant (IMVT) Following Q2 2026 Earnings - MSN
Roivant Sciences buys Immunovant (IMVT) shares worth $349.9m By Investing.com - Investing.com Canada
Roivant Sciences buys Immunovant (IMVT) shares worth $349.9m - Investing.com
Roivant Sciences Ltd. Purchases 16.7 Million Immunovant Shares - TradingView — Track All Markets
Owner Roivant Sciences Ltd Buys 16,666,666 ($350M) Of Immunovant Inc [IMVT] - TradingView — Track All Markets
Immunovant: 'Buy' On Competitive Batoclimab Landscape And IMVT-1402 Advancement - Seeking Alpha
Immunovant Enters Underwriting Agreement for Stock Offering - TradingView — Track All Markets
Immunovant (NASDAQ:IMVT) Stock Price Up 8.1%Here's Why - MarketBeat
Immunovant, Inc. $IMVT is Armistice Capital LLC's 9th Largest Position - MarketBeat
Immunovant drops 7%, prices $550M stock offering - MSN
Immunovant announces $550 million stock offering - MSN
Latham & Watkins Advises on Immunovant’s US$550 Million Offering of Common Stock - Latham & Watkins LLP
Immunovant announces $550 million stock offering and clinical program updates - Investing.com Canada
Roivant Signals Major Pipeline Momentum With Accelerated Timelines - Sahm
Immunovant Announces Roivant President Eric Venker As New CEO: Retail’s Elated - MSN
Immunovant Shares Rise After Pricing $550 Million Stock Offering - marketscreener.com
Immunovant (IMVT) Stock Jumps After $550 Million Share Offering as Graves’ Disease Launch Comes Into Focus - ts2.tech
HighVista Strategies LLC Buys 87,160 Shares of Immunovant, Inc. $IMVT - MarketBeat
Immunovant announces $550 million stock offering and clinical program updates By Investing.com - Investing.com South Africa
Immunovant Announces $550 Million Stock Offering - TipRanks
Immunovant announces pricing of $550 million common stock financing - marketscreener.com
Immunovant Announces Pricing Of $550 Million Common Stock Financing - TradingView — Track All Markets
Immunovant Prices $550 Million Stock Offering - marketscreener.com
Immunovant Announces Pricing of $550 Million Common Stock Financing - The Globe and Mail
Immunovant Inc Stock (IMVT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Immunovant Inc Stock (IMVT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Roivant Sciences Ltd. | Director |
Dec 12 '25 |
Buy |
21.00 |
16,666,666 |
349,999,986 |
113,317,007 |
| Fromkin Andrew J. | Director |
Dec 01 '25 |
Sale |
23.25 |
22,249 |
517,189 |
85,852 |
| Hughes Douglas J. | Director |
Dec 01 '25 |
Sale |
23.24 |
15,000 |
348,665 |
120,773 |
0.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):